SkinPen Microneedling now available! First 6 clients get a discounted rate at $400 for full face - book your appointment NOW! · Book Now!
Redbud Medical Spa
Redbud Medical Spa
Book an Appointment
Medical Weight Loss

The FDA's GLP-1 Compounding Proposal: What It Covers, and What It Does Not

By Krista Hughes, RNNovember 15, 20267 min read

The FDA has not banned compounded semaglutide. In April 2026 it proposed leaving three GLP-1 substances off a list that governs what outsourcing facilities may compound from bulk ingredients, and as of October 17, 2026 that proposal still isn't final.

If you take a compounded GLP-1 for weight loss, you've probably seen a headline this year that read like the door just closed. Those headlines sting. You read one, your stomach goes tight, and you start doing math about your next refill. The document behind the headline is narrower than it sounds. It's a notice about one list, one section of the law, and one kind of compounding facility, written as a proposal: the FDA puts forward a position, takes comment, then decides.

What is compounding, and why would a provider use it?

Compounding means making a medication tailored to one patient's needs. The FDA's own examples are the everyday kind: someone who's allergic to a dye and needs a version made without it, or someone who can't swallow a tablet and needs the same medicine as a liquid. It also lets a provider prescribe a strength, dose, or form no mass-produced product offers, or combine actives a patient would otherwise apply separately.

Two sections of federal law govern it, and they work differently.

Under section 503A, a licensed pharmacy prepares a medicine for one identified patient against a valid prescription. State boards of pharmacy have primary responsibility for the day-to-day oversight of those pharmacies, and the FDA conducts surveillance and for-cause inspections.

Under section 503B, a facility registers with the FDA as an outsourcing facility. It's overseen primarily by the FDA, inspected on a risk-based schedule, and its products are made under Current Good Manufacturing Practice requirements, the federal quality standard for drug manufacturing. It can supply in larger volumes, with or without a prescription for an identified individual patient.

In both cases the care stays with the person who knows you. Your provider evaluates you, decides what to prescribe, sets the dose, and watches how you respond. The pharmacy fills.

What did the FDA propose?

On April 30, 2026 the FDA announced a proposal to exclude semaglutide, tirzepatide, and liraglutide from the 503B bulks list. The notice behind it was published in the Federal Register the next day, May 1, 2026, under Docket FDA-2018-N-3240.

The 503B bulks list is a roster of active ingredients outsourcing facilities may compound from in raw, bulk form. Under section 503B, in most cases an outsourcing facility may not compound a drug from a bulk substance unless that substance appears on the list, or the compounded drug appears on the FDA's drug shortage list at the time of compounding, distribution, and dispensing.

All three substances had been nominated for that list, and the notice proposes not to add them. In announcing the proposal, the FDA said it "did not identify a clinical need for outsourcing facilities to compound semaglutide, tirzepatide, and liraglutide from bulk drug substances."

Because they're not on the list now, the question in front of the agency is whether they're ever added, not whether something already in place is removed.

Which kind of compounding does the proposal cover?

Outsourcing facilities, compounding from bulk drug substances. That's the scope of the document.

The notice is a 503B document from beginning to end. It discusses what an outsourcing facility may use and the list it may draw from. It does not discuss section 503A, the route where a licensed pharmacy prepares a medicine for one identified patient against one prescription. Its single reference to 503A is a footnote contrasting the two sections on manufacturing-practice requirements, and the FDA's press announcement doesn't mention 503A at all.

The two sections set different conditions, are overseen by different bodies, and are changed by different documents. A proposal about which bulk ingredients an outsourcing facility may draw from is a proposal about outsourcing facilities.

Where does the proposal stand right now?

It's published, and it isn't law.

The FDA invited comments through the docket and then widened the window: a notice published on June 26, 2026 moved the deadline to July 30, 2026, after a request for more time. That period has closed. The agency has said it "will consider submitted comments before making a final determination," and that it may seek advice from its Pharmacy Compounding Advisory Committee.

As of October 17, 2026, no final determination has been published in the Federal Register, and the most recent docket entry is the June extension.

What does this mean if you take a compounded GLP-1?

The rules that govern your prescription today are the same ones that governed it before this notice was published, and keeping up with them is your provider's job rather than yours.

Section 503A turns on a clinical judgment. Where a provider determines and documents that a patient needs something meaningfully different from a commercially available product, federal law sets out a place for that decision. It's a clinical call, recorded in your chart, made by the person who examined you.

Compounding rules do move, and the FDA revisits them on its own schedule. When a change affects how a medicine is prescribed, it reaches you through your provider, who adjusts the plan with you. You'll hear it from the person managing your care, not from a push alert at eleven at night. A proposal at the comment stage isn't that moment.

What a GLP-1 program looks like at Redbud

Medical weight loss at Redbud is provider-led, and it starts with a conversation rather than a form. You sit down in a warm, unhurried room and go through your health history, your goals, and anything that shapes which medicine makes sense for you. If a GLP-1 is a good fit, you start low, adjust as you respond, and check in as you go. Nobody is moving you through a queue.

Redbud prescribes GLP-1 medicines, semaglutide and tirzepatide, through licensed compounding pharmacies. The provider prescribes, doses, and monitors; the pharmacy fills.

For the medicines themselves rather than the regulatory question, our posts on semaglutide and tirzepatide compared with semaglutide cover how they work and what to expect. You can meet the team on our providers page, and general treatment questions are answered on our FAQ page.

Frequently asked questions

Did the FDA ban compounded semaglutide?

No. The FDA published a proposal, not a ban. It proposed not to add semaglutide, tirzepatide, and liraglutide to the 503B bulks list, which governs the bulk ingredients outsourcing facilities may compound from. As of October 17, 2026 the agency hasn't issued a final determination.

What is the 503B bulks list?

It's the FDA's roster of active ingredients registered outsourcing facilities may compound from in raw form. Under section 503B, in most cases an outsourcing facility may not compound from a bulk substance unless that substance is on the list, or the compounded drug is on the FDA's drug shortage list at the time of compounding, distribution, and dispensing.

Does the proposal cover the prescription my provider writes for me?

The notice addresses outsourcing facilities compounding from bulk substances under section 503B. It does not address section 503A, the route where a licensed pharmacy prepares a medicine for one identified patient against a valid prescription. Which rules apply to your medicine is something your provider tracks, and will tell you about if it changes.

When will the FDA decide?

The agency hasn't said. The comment period, extended once, closed on July 30, 2026, and the FDA has said it will consider the comments before making a final determination. No final determination had been published as of October 17, 2026.

Still have questions about your GLP-1?

If the headlines left you uneasy, bring it up at your next visit, or book a consultation and we'll talk it through. It's a warmer conversation in person than it is alone with your phone. More on semaglutide and tirzepatide at Redbud.

Disclaimer: This article is for general education and is not medical advice. It describes the status of a federal proposal as of October 17, 2026; regulatory status can change, so ask your provider for the current picture. GLP-1 medicines are prescription treatments, and whether one is right for you, and at what dose, is a decision to make with a licensed provider who knows your health history. Compounded preparations are not FDA-approved products, and the FDA does not review them before they are marketed. Individual results vary. Talk with a Redbud provider before starting or changing any treatment.

Sources

Krista Hughes, RN

Aesthetic Nurse Injector at Redbud Medical Spa

Ready to Explore Your Options?

Book an appointment with one of our providers.